Full Text
Potential Cost-Effectiveness of Neratinib Following Trastuzumab Therapy for Treatment of Early-Stage Her2-Positive Breast Cancer

Abstract

Authors

NR Schwartz L Steuten JB Babigumira JA Roth

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×